Abstract:Intracerebral hemorrhage (ICH) is the most common subtype of stroke, with high disability, fatality, and morbidity as distinct clinical features, and it is a disease that brings a serious burden to society. [ 1 , 2 ] Globally, the incidence of ICH is generally lower in developed countries than in cerebral infarction, but it accounts for far more of all strokes in many Asian and low-income countries than in developed countries, [ 3 ] and China faces a greater burden of ICH than other countries. [ 4 , 5 ] In China, the case fatality rate of cerebrovascular diseases is 14.49 per 100,000, accounting for 22% of the total mortality rate of Chinese residents. [ 4 , 5 ] ICH patients accounted for 14.9% of all stroke patients, and ICH patients died in hospital/unordered hospital accounted for 19.5%, 30% to 50% of ICH patients with in-hospital hemorrhage died within 6 months of onset, and only 12% to 39% of ICH patients survived independently for a long time. [ 6 , 7 ] A study based on Chinese population shows that the prevalence of stroke in China and most provinces has continued to rise in the past years (2013–2019). [ 8 ] Clinical research data show that standardized treatment and specialized care can significantly reduce the mortality of patients with ICH and improve the clinical outcomes of patients with ICH. [ 9 , 10 ] However, early identification of patients with ICH with different clinical outcomes remains difficult, mainly due to the lack of biomarkers that predict the prognosis of patients with ICH.

Serum IL-31 is related to the severity and 3-month prognosis of patients with Intracerebral hemorrhage